Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Cancer patients likely to be suffering from PTSD

24 Nov 2019
Anxiety and stress over test results is just one of the few risks faced by individuals who carry out genetic testing.

Post-traumatic stress disorder is highly common among cancer patients and correlates with distress, depression and anxiety, a recent study has found.

Researchers enrolled 1,017 adult cancer patients (mean age, 57.6±14.4 years; 513 males) who were asked to accomplish the Post-traumatic Symptom Scale (PTSS-10) and Hospital Anxiety and Depression Scale (HADS). Breast, haematological and lung malignancies were the most common cancers in the sample.

The median PTSS-10 score was 9 points. Majority (68.3 percent; n=695) scored below 12.5 points. Analysis according to sex showed that females were significantly more likely than males to clear the 12.5-point score threshold (24.5 percent vs 38.9 percent; p<0.001).

In comparison, the median HADS anxiety score was 6 points, with most of the participants (63.1 percent; n=642) scoring less than 8 points; 22.3 percent (n=227) scored between 8 and 11 points, while the remaining 14.6 percent (n=148) scored above 11 points. Females were again significantly more likely to surpass 11 points (20.4 percent vs 8.6 percent; p<0.001).

The median depression score was 4 points, with only 13.2 percent scoring above 11 points. Majority (72.5 percent; n=737) fell below the 8-point cutoff. There was no observable gender effect for depression.

Scores in the PTSS-10 correlated significantly with the depression (coefficient, 0.637) and anxiety (coefficient, 0.708) subscales of the HADS, and with the HADS total score (coefficient, 0.744; p-all<0.01). All correlations were of large magnitudes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.